Medicenna Therapeutics Corp. (MDNA): Price and Financial Metrics
MDNA Price/Volume Stats
| Current price | $0.16 | 52-week high | $0.84 |
| Prev. close | $0.18 | 52-week low | $0.15 |
| Day low | $0.15 | Volume | 1,267,200 |
| Day high | $0.20 | Avg. volume | 160,047 |
| 50-day MA | $0.30 | Dividend yield | N/A |
| 200-day MA | $0.51 | Market Cap | 10.93M |
MDNA Stock Price Chart Interactive Chart >
Medicenna Therapeutics Corp. (MDNA) Company Bio
Medicenna Therapeutics Corp. operates as an immuno-oncology company. The Company develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. Medicenna Therapeutics offers its services in Canada.
Latest MDNA News From Around the Web
Below are the latest news stories about MEDICENNA THERAPEUTICS CORP that investors may wish to consider to help them evaluate MDNA as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to dive into the biggest pre-market stock movers as we start the trading week on Monday with the hottest coverage! |
Dear LUNR Stock Fans, Mark Your Calendars for Jan. 12Intuitive Machines stock is rising on Monday after the company announced plans for a lunar mission launch in January 2024. |
Why Is Medicenna Therapeutics (MDNA) Stock Down Today?Medicenna Therapeutics stock is falling on Monday after the company announced that shares of MDNA will be delisted from the Nasdaq. |
Medicenna Announces Nasdaq Delisting and Cutback of Management TeamThe Company’s listing on the Toronto Stock Exchange will not be impactedTORONTO and HOUSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of engineered cytokines, announced today that the Company received a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”), which notified the Company of the delist |
Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid TumorsNew data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting on November 4, 2023 Company expects to report initial results from both the monotherapy and combination arms of the Phase 2 dose expansion study in H1 2024 TORONTO and HOUSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company foc |
MDNA Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | -18.91% |
| 1-year | -75.76% |
| 3-year | -95.80% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -71.90% |
| 2021 | -65.17% |
| 2020 | 80.00% |
| 2019 | 401.74% |
Loading social stream, please wait...